TrianglePUBLICATIONS · 22665903
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Clin Cancer Res
- Publication date
- 2012 Jul 15
- First author
- Thornton K
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Thornton K
- type
- Author
- name
- Kim G
- type
- Author
- name
- Maher VE
- type
- Author
- name
- Chattopadhyay S
- type
- Author
- name
- Tang S
- type
- Author
- name
- Moon YJ
- type
- Author
- name
- Song P
- type
- Author
- name
- Marathe A
- type
- Author
- name
- Balakrishnan S
- type
- Author
- name
- Zhu H
- type
- Author
- name
- Garnett C
- type
- Author
- name
- Liu Q
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Thornton K
- type
- Author
- name
- Kim G
- type
- Author
- name
- Maher VE
- type
- Author
- name
- Chattopadhyay S
- type
- Author
- name
- Tang S
- type
- Author
- name
- Moon YJ
- type
- Author
- name
- Song P
- type
- Author
- name
- Marathe A
- type
- Author
- name
- Balakrishnan S
- type
- Author
- name
- Zhu H
- type
- Author
- name
- Garnett C
- type
- Author
- name
- Liu Q
- type
- Author
- bibliography ids
- nci-bib-801a690d6906d5dc309f4606
- book metadata
- content sha256
- a36df5a876568ecd72b560f492afffc7b7c0ce9b230384ac06eeca350a6cad4f
- document type
- citation
- dois
- 10.1158/1078-0432.CCR-12-0411
- electronic publication date
- display
- 2012 Jun 4
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:22665903
- immutable id
- pubmed:22665903@a36df5a876568ecd72b560f492afffc7b7c0ce9b230384ac06eeca350a6cad4f
- journal
- abbreviation
- Clin Cancer Res
- issn electronic
- 1557-3265
- issn print
- 1078-0432
- issue
- 14
- name
- Clinical cancer research : an official journal of the American Association for Cancer Research
- nlm unique id
- 9502500
- pages
- 3722-30
- volume
- 18
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 22665903
- provenance
- batch id
- c95be1d0b8cf19942816
- provider
- NCBI PubMed ESummary
- record sha256
- f98c6f5232f3087e383380070b745da2507b03ee3ba5513c1864094527b85536
- response sha256
- a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
- retrieved at
- 2026-09-09T23:46:47.691937+00:00
- publication date
- display
- 2012 Jul 15
- precision
- day
- year
- 2012
- publication types
- Journal Article
- Randomized Controlled Trial
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Preserved source evidence · Not medical advice